Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05522907 | Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer | unknown | — | 1,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 31, 2022 |
| NCT05512663 | Safety and Efficacy Evaluation of Transperineal Irreversible Electroporation (IRE) of Anterior Prostate Cancer | unknown | N/A | 10 | Jewish General HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05285319 | Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer | unknown | Phase 2 | 82 | Cairo UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04796467 | 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 50 | Peking Union Medical College HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05258526 | Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study)(BENEFIT-CA) | unknown | N/A | 80 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05481372 | PINPOINT Feasibility Study | unknown | N/A | 14 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05017181 | Novel MRI Assessment of Prostate Cancer VALIDATE-PRO(VALIDATE-PRO) | unknown | — | 234 | University College, LondonOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04996602 | Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05455736 | STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational Study(STARR) | unknown | — | 90 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05427864 | Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging | unknown | N/A | 47 | Gulhane Training and Research HospitalOTHER_GOV | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05430737 | A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer | unknown | N/A | 60 | West China HospitalOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04116775 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | unknown | Phase 2 | 32 | Julie Graff, MDFED | 1 | Jun 23, 2022 | clinicaltrials |
| NCT03284151 | Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma | unknown | — | 26 | Centre Francois Baclesse, LuxembourgOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05252806 | Quantitative mpMRI to Predict Metastatic Potential of Prostate Cancer(QmpMRI) | unknown | — | 30 | Radboud University Medical CenterOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05078359 | Optimizing Positive Predicting Value of Prostate MRI(PROMOD) | unknown | — | 5,000 | Ospedali Riuniti di FoggiaOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03588819 | Stereotactic MRI-Guided Radiation for Localized Prostate Cancer(2SMART) | unknown | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04278261 | Comparison H-FIRE and Laparoscopic RP in Treating Men With Localized Prostate Cancer | unknown | N/A | 216 | Shanghai East HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05382182 | Outcome Of Treatment Of Prostate Cancer at Sohag University Hospital Between 2017 to 2021 | unknown | — | 100 | Sohag UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT04718987 | Potency pReservation In Prostate cAncer Patients Treated With UltraSound-guided Low-dose Rate Brachytherapy(PRIAPUS) | unknown | N/A | 10 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05187949 | Promoting Shared-decision Making in Opportunistic Screening for Prostate Cancer(PROSHADE) | unknown | — | 1,781 | Universidad Miguel Hernandez de ElcheOTHER | 0 | May 17, 2022 | clinicaltrials |
| NCT04235556 | Integrated Care Pathway in Oncology (PASSION)(PASSION) | unknown | — | 1,800 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04854343 | SLPI for Prostate Cancer | unknown | — | 280 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03235687 | Decision Impact Trial of the ExoDx Prostate (IntelliScore) | unknown | N/A | 1,000 | Exosome Diagnostics, Inc.INDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT04251546 | Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV | unknown | — | 80 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05355727 | PROSAIC-DS Study (PROState AI in Cancer - Decision Support)(PROSAIC-DS) | unknown | N/A | 1,040 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04300673 | Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients(DETECT) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05297162 | PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective Trial(PROSPET-BX) | unknown | N/A | 128 | Istituto Clinico HumanitasOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03961737 | Study of the Response to Irradiation on Prostatic Explants ex Vivo, as a Predictive Factor of the Clinical Response to Irradiation of Prostate Cancers(EXPLANT) | unknown | N/A | 92 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05327621 | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05319145 | PeRsonalizing the Approach to the Oncologic Frail Individual Through Tailored Assessment and Intervention (PROFIT Study)(PROFIT) | unknown | N/A | 268 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 2 | Apr 13, 2022 | clinicaltrials |
| NCT04773821 | Performance of Prostate MRI and Following Biopsy to Detect Prostate Cancer Recurrence After Focal Therapy(IRMProft) | unknown | N/A | 260 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03238170 | MR-simulation in Radiotherapy for Prostate Cancer(FIMRA-P) | unknown | N/A | 40 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05286840 | 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer | unknown | Phase 1 / Phase 2 | 150 | Luke Nordquist, MDOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05212857 | Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05192694 | Evaluation of Fapi-pet in Prostate Cancer.(FAPIPETPCA) | unknown | N/A | 40 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03526510 | Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer | unknown | N/A | 178 | Dr. Patrick CheungOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03572621 | Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality(PRODUCAN) | unknown | N/A | 240 | Hospices Civils de LyonOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT05262608 | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation(PROspect) | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05248282 | Clinical Validation of the Prognostic Value of the PrTS on Prostate Cancer Patients | unknown | — | 150 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05224024 | Retzius-sparing Technique in Robotic-assisted Radical Prostatectomy | unknown | N/A | 80 | Ankara UniversityOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05187026 | Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy(ePRO-PCaRT) | unknown | — | 300 | Helsinki University Central HospitalOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05188911 | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | unknown | — | 30 | Fudan UniversityOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT05180305 | A Study to Assess Mitomic Prostate Test for Prostate Cancer Screening | unknown | — | 200 | TSH Biopharm Corporation LimitedINDUSTRY | 1 | Jan 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2022source: clinicaltrials